DRIVIN G ROWTH - Dr. Reddy's
DRIVIN G ROWTH - Dr. Reddy's
DRIVIN G ROWTH - Dr. Reddy's
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
38<br />
directors’ report<br />
Euro 144 thousands for the previous year<br />
ended March 31, 2001.<br />
KUNSHAN ROTAM REDDY<br />
PHARMACEUTICAL CO. LTD.<br />
DURING THE YEAR 2001-02, your<br />
Company increased its stake in the share<br />
capital of Kunshan Rotam Reddy<br />
Pharmaceutical Co. Ltd to 51%. The<br />
Company is engaged in marketing of active<br />
pharmaceutical ingredients, intermediates<br />
and formulations in China. The Company<br />
recorded a turnover of RMB 5,018<br />
thousands and a net loss of RMB 13,664<br />
thousands for the year ended December 31,<br />
2001.<br />
REDDY ANTILLES N.V.<br />
DURING THE YEAR 2001, no royalty<br />
income was received by Reddy Antilles N.V..<br />
The Company recorded a net loss of US$ 15<br />
thousands during the year ended December<br />
31, 2001 as against a net loss of US$ 1,248<br />
thousands for the year ended December 31,<br />
2000.<br />
REDDY NETHERLANDS B.V.<br />
REDDY NETHERLANDS B.V. is a<br />
wholly owned subsidiary of Reddy Antilles<br />
N.V.. During the year ended December 31,<br />
2001, no royalty income was received by<br />
DR. REDDY’S LABORATORIES LTD. | DIRECTORS’ REPORT | ANNUAL REPORT 2001-2002<br />
the Company. The subsidiary recorded a net<br />
loss of NLG 79 thousands for the year<br />
ended December 31, 2001 as against a net<br />
loss of NLG 345 thousands for the year<br />
ended December 31, 2000.<br />
REDDY PHARMACEUTICALS<br />
SINGAPORE PTE LTD.<br />
REDDY PHARMACEUTICALS<br />
Singapore Pte Ltd. a wholly owned<br />
subsidiary of Reddy Antilles N.V., recorded a<br />
turnover of S$ 1,003 thousands for the year<br />
ended December 31, 2001 as against<br />
S$ 4094 thousands for the year ended<br />
December 31, 2000, a decrease of 75.5%.<br />
The Company registered a net loss of S$ 98<br />
thousands for the year ended December 31,<br />
2001 as compared to a net profit of S$ 113<br />
thousands in the previous year.<br />
REDDY US THERAPEUTICS, INC.<br />
REDDY U.S. THERAPEUTICS, Inc. is<br />
a subsidiary of Reddy Antilles N.V.. The<br />
Company’s objective is to discover novel<br />
therapeutics that addresses un-met medical<br />
needs in diabetes, inflammation, lipid<br />
metabolism, oncology and cardiovascular<br />
disease. Their technology platform, the CMS<br />
Pathway, links cell matrix signaling to<br />
endothelial cell function, smooth muscle<br />
cell function and disease. The CMS
Change language